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Special Article
Effect of saffron supplementation on symptoms of depression
and anxiety: a systematic review and meta-analysis
Wolfgang Marx, Melissa Lane, Tetyana Rocks, Anu Ruusunen, Amy Loughman, Adrian Lopresti,
Skye Marshall, Michael Berk, Felice Jacka, and Olivia M. Dean
Context: Saffron (Crocus sativus L.) has gained interest as a potential treatment in
psychiatry. Objective: This systematic review and meta-analysis sought to investi-
gate the effect of saffron supplementation, as both an adjunctive therapy and
monotherapy, on symptoms of depression and anxiety in clinical and general popu-
lations compared with pharmacotherapy or placebo. Data sources: Using the
PRISMA guidelines, a systematic literature review of randomized controlled trials
was conducted. Data extraction: A meta-analysis was conducted to determine
treatment effect. Risk of bias was assessed using the Jadad scale. Results: Twenty-
three studies were included. Saffron had a large positive effect size when compared
with placebo for depressive symptoms (g ¼ 0.99, P < 0.001) and anxiety symp-
toms (g ¼ 0.95, P < 0.006). Saffron also had a large positive effect size when used
as an adjunct to antidepressants for depressive symptoms (g ¼ 1.23, P ¼ 0.028).
Egger’s regression test found evidence of publication bias. Conclusions: Saffron
could be an effective intervention for symptoms of depression and anxiety;
however, due to evidence of publication bias and lack of regional diversity, further
trials are required. PROSPERO registration CRD42017070060.
INTRODUCTION
Saffron (Crocus sativus L.) and its constituents, includ-
ing crocin, crocetin, and safranal, may have a positive
effect on several neurobiological mechanisms impli-
cated in mental illness.1–3 In animal models, whole saf-
fron and implicated compounds have been reported to
modulate pathways related to neurotransmitters,
immune regulation, inflammation, oxidative stress, the
hypothalamus-pituitary-adrenal (HPA) axis, and neuro-
trophins.4 For example, in rats, the administration of a
saffron extract dose-dependently increased brain con-
centrations of dopamine and, at high doses, increased
glutamate levels.5 In another study, the administration
of crocin modulated serotonergic activity in rats ex-
posed to the nonselective serotonin receptor agonist
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meta-chlorophenylpiperazine, lowering obsessive-like
behaviors.6 Saffron constituents also have anti-
inflammatory, immune-regulating, and antioxidant
properties, including the modulation of endogenous an-
tioxidant enzymes.7–11 In addition, studies using animal
stress models have confirmed that saffron modulates
HPA axis activity by reducing plasma corticosterone
concentrations.12,13 Finally, support for the neuropro-
tective effects of saffron and its constituent, crocin, is
derived from studies demonstrating positive effects on
the neurotrophin, brain-derived neurotrophic factor
(BDNF) in animal stress models.14,15
Two previous meta-analyses have reported saffron
supplementation to improve measures of depression in
clinical trials.16,17 Previous meta-analyses on this topic,
however, have only examined the effects of saffron on
depression in clinical populations with mild to major
depression.16,17 Furthermore, since the publication of
these reviews, several published intervention studies
have been conducted in both depression and other
mental illnesses. Therefore, using the Preferred
Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) guidelines, this systematic review
and meta-analysis of randomized controlled trials
(RCTs) aims to examine the transdiagnostic effects of
saffron supplementation (as a stand-alone or adjunctive
intervention) on symptoms of mental illness in both




This review was written in accordance with the
PRISMA (Preferred Reporting Items for Systematic
reviews and Meta-Analyses) statement (see Appendix S1
in the Supporting Information online)18 and was pro-
spectively registered on PROSPERO
(CRD42017070060). A search strategy was developed
based on the research question (Table 1). Studies were
identified using the following databases: Medline
(Pubmed), PsychInfo, Embase, the Cochrane Library,
and CINAHL. Search terms were related to saffron and
its constituents (“saffron” OR “crocus” OR “crocin” OR
“crocetin”) and mental health outcomes (“depression”
OR “depressive disorder” OR “anxiety disorders” OR
“affective symptoms” OR anxi* OR mood OR
“psychological symptoms” OR “psychological distress”).
The search strategy identified articles published since
journal inception up to March 2018.
Studies were required to be RCTs, including cross-
over studies; be published in English; include measures
of mental health (eg, depression, low mood, depressive
symptoms, emotional problems, and anxiety); and use
any component of saffron (eg, whole saffron, standard-
ized extracts, parts of saffron, or specific saffron-derived
compounds). Interventions that included saffron in
combination with standard medications were included;
however, combined interventions with other novel
ingredients were excluded. No limit on age or popula-
tion was included, and the comparator could be either
placebo or pharmacotherapy.
Data extraction
Two authors independently screened individual studies
in duplicate, with disagreements resolved by consensus
or a third author. Using a standardized and piloted ex-
traction form, the following parameters were extracted
from included studies: author/date, study design, sam-
ple size, total study period, population characteristics
(including age, sex, and comorbidities), intervention
characteristics (including dose, type, and duration of
exposure, concomitant treatment), length of follow-up,
adverse events, and mental health–related outcomes, in-
cluding measures of depression, anxiety, mood.
Outcomes not related to mental health were not
extracted for this review.
Assessment of study risk of bias
Risk of bias was assessed using the Jadad scale, a 5-item
tool that assesses risk of bias due to randomization,
blinding, and follow-up.19 Studies can receive a score
between 0 and 5, with a higher score indicating a lower
risk of bias.
Statistical analyses
The meta-analyses were conducted in Comprehensive
Meta-Analysis 3.020 using a DerSimonian-Laird ran-
dom-effects model21 to account for heterogeneity be-
tween studies. The primary outcome was the effect of
saffron on total depressive symptoms in comparison
with placebo control conditions. The effect of saffron
on symptoms of depression as an adjunctive to medica-
tion and as a stand-alone intervention compared with
medication was also computed as a secondary outcome.
The effects of saffron on symptoms of anxiety compared
with placebo, medication, and as an adjunctive inter-
vention were also computed when sufficient data were
available. Mean change scores in symptoms for saffron
and control conditions were compared using random-
effects meta-analyses to compute effect size of saffron
compared with control condition as Hedges’ g (with
95%CI). For studies that used >1 measure of the same
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outcome, the measure identified as the primary out-
come by the respective study was used in meta-analyses.
Otherwise, an average change score across all measures
was computed and used in the pooled analysis. In
multi-arm trials that had >1 active saffron condition, a
pooled effect was computed across all saffron arms
compared with the nonsaffron comparator conditions.
To examine the possibility of publication bias affecting
results, Egger’s t test was conducted. Finally, to further
account for the potential impact of publication bias, a
Duval and Tweedie’s trim-and-fill analysis was applied
to recalculate effect sizes after statistically accounting
for outlier studies.
Additionally, subgroup analyses were conducted to
examine the 1) effects of saffron in comparison with an-
tidepressant medications and 2) the effect of saffron on
depression when used as an adjunctive treatment along-
side antidepressants (ie, studies comparing saffron to
placebo in samples already taking or commencing anti-
depressant medications).
Heterogeneity between studies was examined using
Cochran’s Q (with P value) and I2 estimates. These sta-
tistics estimate the extent to which statistical hetero-
geneity between studies has arisen from genuine
interstudy differences rather than chance.
RESULTS
Study selection
As represented in Figure 1, the search strategy resulted
in 310 de-duplicated studies that were screened to iden-
tify 23 eligible studies for inclusion (see Table 222–44).
Study characteristics
A total of 1237 participants were enrolled in the in-
cluded studies, with 30–128 participants in each study.
Trials ran 4–12 weeks with 6 weeks being the most
common trial length (n ¼ 9/23). Seventeen studies in-
vestigated saffron monotherapy (n ¼ 11 studies) or saf-
fron as an adjunctive pharmacotherapy compared with
placebo (n ¼ 6 studies). Six studies compared saffron
monotherapy with an antidepressant medication (in-
cluding fluoxetine,23,32,40,42 imipramine,25 and citalo-
pram27) No study investigated saffron as an adjunct to
psychotherapy. Nineteen studies included participants
with either clinical diagnosis of mental illness or clinical
symptoms of mental illness using a validated tool. The
average age of participants was 39 years, with a range of
14–57 years. Most studies included a mix of sexes, with
5 studies including only females and 1 study including
only males. Most studies were conducted in Iran (n ¼
21/23), with 2 studies conducted in Australia.34,35
Thirteen studies were conducted by the same research
group. Risk of bias across most studies was low, with 20
studies receiving a score of 4 or 5 (out of 5) on the
Jadad Scale (see Appendix S2 in the Supporting
Information online).
Interventions
Most studies (n ¼ 19/23) used a dose of 30 mg per day
of saffron. Ten studies used the stigma of saffron, 4
studies used saffron petals, 3 used crocin only, and the
remaining studies used either a whole powder or did not
provide further details. In 9 studies, the intervention was
standardized to contain either crocin, safranal, or lepti-
crosalides (a measure of bioactive compounds present in
saffron, including safranal and crocin isomers).
Outcome measures
Depressive symptoms (n ¼ 22/23) were more com-
monly investigated than anxiety symptoms (n ¼ 8/23).
Depression and/or anxiety symptoms were measured
using the Hamilton Rating Scale for Depression or
Anxiety, Beck Depression Inventory, Depression
Anxiety Stress Scale (DASS) 21, or Revised Child
Anxiety and Depression Scale (RCADS; youth and par-
ent versions). One study assessed mood using the
Profile of Mood States (POMS) and Positive and
Negative Affect Schedule (PANAS) 21 tools.
Study results
Effects of saffron on depressive symptoms. Random-
effects meta-analysis found a significant and large
positive effect size for saffron reducing symptoms of de-
pression in comparison with placebo (g ¼ 0.99,
95%CI ¼ 0.61–1.37, n ¼ 14 studies, n ¼ 716 partici-
pants, P < 0.001; Figure 222–27,29–31,33–40,42,44). An addi-
tional study that could not be entered into the meta-
analysis due to insufficient available data also found
that saffron significantly improved depressive symp-
toms compared with placebo (P < 0.0001).43 There was
significant heterogeneity across the study data (Q ¼
Table 1 PICOS criteria for inclusion and exclusion of
studies
Parameter Criteria
Population Human participants, both clinically diagnosed
with a mental illness and otherwise
Intervention Saffron supplementation. Both whole saffron
or as an extract
Comparator Placebo or standard antidepressant
medication
Outcomes Symptoms of mental illness, adverse events
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71.8, P < 0.001, I2¼81.9%). Egger’s regression test
found strong evidence of publication bias (Intercept ¼
6.99, P ¼ 0.007). The funnel plot of publication bias is
displayed in Appendix S3 in the Supporting Information
online. Correcting for publication bias using a trim-and-
fill analysis increased the effect size of saffron supple-
mentation (g ¼ 1.14, 95%CI ¼ 0.74–1.52).
When compared with antidepressants medica-
tions, there was no significant difference between saf-
fron and medications (g ¼ 0.17, 95%CI ¼ 0.50–0.17,
n ¼ 5 studies, n ¼ 210 participants, P ¼ 0.33;
Figure 222–27,29–31,33–40,42,44). There was a low degree
of heterogeneity across the study data (Q ¼ 6.16, P ¼
0.19, I2 ¼35.1%). One study for which sufficient infor-
mation was not provided to be included in the meta-
analysis also found no significant difference in depressive
symptoms between saffron and medication (P ¼ 0.61).32
Meta-analysis of studies that investigated the effect
of saffron as an adjunct to pharmacotherapy (ie, in
studies comparing saffron to placebo in people taking
antidepressants) reported a large significant benefit
from saffron supplementation (n ¼ 4 trials, n ¼ 144
participants, g ¼ 1.23, 95%CI ¼ 0.13–2.33, P ¼ 0.028,
Q ¼ 27.62, I2¼ 89.1%). One study that could not be in-
cluded in the meta-analysis reported no significant
difference in depressive symptoms between the adjunc-
tive group (fluoxetine and saffron) and control (fluoxe-
tine and placebo) (P ¼ 0.560).41
Effects of saffron on symptoms of anxiety.
Figure 328,34–37,4428,34–37,44 displays the effects of saffron
monotherapy and adjunctive therapy on symptoms of
anxiety across 6 RCTs compared with placebo (n ¼ 375
participants). Random-effects meta-analysis found a
large positive effect size for saffron on reducing symp-
toms of anxiety in comparison with placebo control
conditions (g ¼ 0.95, 95%CI ¼ 0.27–1.63, P < 0.006).
There was significant heterogeneity across the study
data (Q ¼ 44.38, P < 0.001, I2 ¼88.74%). Egger’s regres-
sion test found strong evidence of publication bias
(Intercept ¼ 0.12, P ¼ 0.028). Correcting for publica-
tion bias using a trim-and-fill analysis increased the ef-
fect size of saffron supplementation (g ¼ 1.40, 95%CI ¼
0.60–2.150). There were insufficient studies to conduct
a meta-analysis of the effect of saffron on anxiety in
comparison with antidepressant medications or to con-
duct subgroup analysis of saffron as an adjunctive treat-
ment. One study that investigated the effect of saffron
for anxiety symptoms compared with citalopram found
Figure 1 Flow diagram of the literature search process.
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no significant difference between treatment groups
(P < 0.001).27
Sensitivity analyses. Sensitivity analyses were performed
to exclude 1 outlier study that could be influencing the
overall findings.44 Exclusion of this study only slightly
reduced the overall effect size of saffron on depressive
symptoms compared with placebo (g ¼ 0.84, 95%CI ¼
0.53–1.16, P < 0.001), although large heterogeneity
(Q ¼ 45.45, P < 0.001, I2¼73.8%) and significant publi-
cation bias was still evident in the remaining 13 studies
(Egger’s regression intercept ¼ 4.957, P ¼ 0.043).
When performing sensitivity analyses with the out-
lier study excluded for anxiety outcomes, the effects of
saffron compared with placebo were reduced substan-
tially, although overall results remained the same (g ¼
0.48, 95%CI ¼ 0.25–0.70, P < 0.001). There was also lit-
tle indication of heterogeneity (Q ¼ 3.39, P ¼ 0.50,
I2¼0%) or publication bias (Egger’s regression intercept
¼ 0.23, P ¼ 0.47) in the remaining 5 studies, although
this is likely due to standard tests for detecting hetero-
geneity/publication bias in meta-analysis being under-
powered in this small number of studies.
Effects of saffron on additional outcomes. One study
found a significant improvement in total score of mood
disturbances (P < 0.001) and subscales of fatigue (P ¼
0.007), tension (P ¼ 0.025), vigor (P ¼ 0.007), confu-
sion (P ¼ 0.001), negative affect (P ¼ 0.001), and stress
(P < 0.001) when saffron supplementation was com-
pared with placebo.34 Another study found significant
improvements in self-reported measures of internaliz-
ing symptoms (P ¼ 0.049), separation anxiety (P ¼
0.003), and social phobia (P ¼ 0.023) compared with
placebo.35 General mental health was improved in 1
study compared with placebo (P < 0.001),44 and the
emotional functioning subscale of a quality-of-life ques-
tionnaire also improved in a separate study after saffron
supplementation compared with placebo (P < 0.001).22
Adverse events
Adverse events were reported for most studies (n ¼ 21/23).
Headache, nausea, anxiety, constipation, dry mouth,
and appetite changes were the most commonly reported
symptoms in both arms. No study found symptoms to
occur in the saffron group at a statistically higher rate
than in the placebo and medication groups.
DISCUSSION
This is the most comprehensive meta-analysis to evalu-
ate the effects of saffron supplementation for depressive
and anxiety symptoms. The inclusion of adult,
adolescent, and subclinical depressive and anxiety pop-
ulations, as well as the examination of both depression
and anxiety outcomes, provides a greater understanding
of the possible efficacy of saffron as an intervention
across the common mental disorders.
The results of this meta-analysis are consistent with
2 prior meta-analyses that investigated saffron for mild-
to-major depression only.16,17 Saffron had a significant
large positive effect size when compared with placebo
for both depression (g ¼ 0.99, P < 0.001) and anxiety (g
¼ 0.95, P < 0.006) outcomes. For depressive outcomes,
saffron also had a significant large positive effect size
when used as an adjunctive treatment to antidepres-
sants (g ¼ 1.23, P ¼ 0.028), and when compared with
antidepressant medications, there was no significant
difference between groups (g ¼ 0.17, P ¼ 0.33). The
included studies demonstrate that saffron supplementa-
tion appears to be well-tolerated with few adverse events
being reported by the included studies or by other
authors.45 However, all studies to date have been of rel-
atively short duration and with a limited sample size.
Therefore, longer-term trials that are suitably powered
are required to assess the safety of saffron
supplementation.
In the context of standard interventions for depres-
sion and anxiety, the results from the placebo-
controlled trials suggest an effect size that is consider-
ably greater than standard pharmacotherapy, such as
selective serotonin reuptake inhibitors (Cohen’s d ¼
0.30).46 However, the 5 trials directly comparing saffron
with antidepressant medication found no statistically
significant difference (P ¼ 0.33). Due to the large effect
sizes, the publication bias detected for both outcomes,
and the majority of trials being conducted in 1 region,
many by the same research group (n ¼ 13/23), there is
a need to replicate these results within other popula-
tions and in large, well-powered, rigorous trials before
clinical recommendations are justified. Similarly,
greater rigor regarding good manufacturing practice
and standardization, dosage, and characterization of the
active ingredients is needed.
In addition to the need to replicate existing studies,
additional areas are recommended for future studies.
First, the use of saffron for other mental illnesses is cur-
rently underexplored. Whereas 7 studies assessed anxi-
ety symptoms, only 1 study included participants with a
diagnosed anxiety disorder. Similarly, 1 study evaluated
the safety and feasibility of saffron in schizophrenia, but
no efficacy trials have been conducted to date.47
Furthermore, there is a need to explore comparative ef-
ficacy of the different components of saffron. One study
found that saffron petal and stigma had equivalent effi-
cacy in treating depressive symptoms in participants
with major depression, but there is insufficient
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literature to comment on particular components at this
stage.23 Because of the high cost of saffron for culinary
use, previous reviews have recommended the investiga-
tion of the efficacy of less expensive parts of saffron (eg,
petal and corm).4 However, because of the small thera-
peutic dosage used in current studies, the cost of saffron
formulations is unlikely to be considerably higher than
for other nutraceutical interventions.
Preclinical studies suggest that compounds con-
tained within saffron have a range of potentially rele-
vant mechanisms of action, including antioxidant and
anti-inflammatory properties, and are able to modulate
BDNF expression and the HPA axis.4 However, these
pathways have been largely unexplored within clinical
trials. Hence, there is a need to measure markers of rele-
vant pathways within future clinical trials to explore the
association between changes in these biological markers
and clinical symptoms. Furthermore, as demonstrated
by Rapaport et al,48 who reported that treatment re-
sponse to n-3 (eicosapentaenoic acid) was greater in
those with higher inflammation at baseline, measuring
relevant biomarkers may provide valuable information
regarding specific populations and participant stratifica-
tion to determine who is likely to respond to saffron
treatment. Related to this is the need for dose-finding
studies to establish the optimal dosing regimen. Most
studies have used 30 mg of saffron per day; however, it
is unclear whether there are other regimens that may
improve the therapeutic effect.
CONCLUSION
In summary, the existing evidence suggests a potential
for saffron to be an efficacious intervention for symp-
toms of depression and anxiety. However, the strength
of this conclusion is moderated by the lack of large-
scale trials and risk of publication bias among the many
small-scale pilot trials published on this topic. Indeed,
the large effect sizes reported for some studies require
replication in further clinical trials that address method-
ological limitations and the lack of regional diversity be-
fore clinical recommendations can be made. Trials that
Figure 2 Meta-analysis showing effects of saffron on symptoms of depression in a) comparison with antidepressant medications,
and b) comparison with placebo controls. Box size represents study weighting. Diamond represents overall effect size and 95% confi-
dence intervals.
Figure 3Meta-analysis of the effects of saffron on symptoms of anxiety. Box size represents study weighting. Diamond represents overall
effect size and 95% confidence intervals.
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explore the mechanisms of action of saffron, dosage, ac-
tive ingredients, long-term safety, and the efficacy in di-
agnosed mental illnesses are also required.
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